Citius (CTXR) Market Update
Trading performance
- Closing price: USD 0.42 (down 6.96 % from the previous close).
- 24‑hour volume: USD 225.5 k.
- Shares outstanding: 27.5 million.
- Market capitalization: USD 12.6 million.
Historical context
- Since the end of last month, the share price has declined 25.82 %.
- 200‑day simple moving average: USD 0.68.
- 52‑week high: USD 1.98 (recorded 10/24/2025).
- 52‑week low: USD 0.41 (recorded 10/19/2026).
Peer Performance (Last 24 Hours)
| Company | Ticker | % Change | Current Price (USD) | Market Cap (USD) | Key Note |
|---|---|---|---|---|---|
| T3 Defense | DFNS | –1.24 % | 4.93 | 14.5 million | – |
| Actuate Therapeutics | ACTU | –0.99 % | 0.59 | 14.5 million | Filing an amended registration statement for a public offering of common stock and warrants. |
| Dyadic | DYAI | –7.32 % | 0.38 | 15 million | – |
| Heartsciences | HSCS | +1.66 % | 3.24 | 14.6 million | Filing a definitive proxy statement for a merger with Fortitude Mining Holdings, Inc. |
| Bionano Genomics | BNGO | –2.4 % | 1.26 | 14.7 million | Filing a Schedule 13G reporting ownership by related parties. |
Company Overview
Citius Pharmaceuticals, Inc. is a late‑stage biopharmaceutical firm headquartered in Cranford, United States. The company focuses on developing and commercializing a pipeline of anti‑infectives for adjunct cancer care, oncology, stem cell therapy, and prescription products. It trades on the Nasdaq stock exchange under the ticker CTXR.
